ArticleFrontiers in medicine2025
Trends in immune cell profiles of osteomyelitis: a clinical study supported by Mendelian randomization analysis.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Combination of single-cell and bulk RNA-seq reveals changes in the immune landscape in osteomyelitis.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Osteomyelitis, a persistent inflammatory bone disease, is only partially responsive to conventional antibiotics and surgery. Some patients experience poor outcomes and relapse. Recently, immunotherapy has emerged as a promising treatment strategy. This study combined clinical research with Mendelian randomization analysis to explore the interaction and relationship between immune cells and osteomyelitis, aiming to offer novel therapeutic insights. Methods: We retrospectively analyzed blood test data from patients admitted between July 1, 2023, and December 31, 2024, including those undergoing internal fixator removal and those with osteomyelitis. Based on the bacterial culture results, patients with osteomyelitis were categorized into four subgroups: Gram-positive, Gram-negative, mixed infections, and culture-negative. The impact of bacterial infections on immune cells was assessed, and two-sample Mendelian randomization was applied to evaluate the bidirectional causality between immune cells and osteomyelitis. Causal effects were primarily estimated using inverse-variance weighted and weighted-median methods, with F-statistic calculations and sensitivity analyses conducted to bolster the credibility of the results. Results: Compared to the internal fixator removal group, patients with osteomyelitis exhibited significantly reduced neutrophils but elevated lymphocytes, eosinophils, and basophils. Subgroup analysis revealed significantly increased lymphocyte counts and decreased neutrophil counts across all subgroups, except for the mixed infection group. Two-sample Mendelian randomization indicated a causal link between circulating lymphocytes and osteomyelitis risk [odds ratio (OR): 1.203; 95% confidence interval (CI): 1.064-1.362; Conclusion: Osteomyelitis was associated with significant alterations in peripheral immune cell counts, particularly lymphocyte counts, which showed a strong positive correlation with the disease risk. These findings pave the way for future immunotherapeutic approaches for the treatment of osteomyelitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.